Type 1 Diabetes Trial, Recruiting (NCT01999374)

Type 1 Diabetes Trial, Recruiting NCT01999374 Sponsor: Rodolfo Alejandro Condition: Type 1 Diabetes

Printed from Voxsanity (voxsanity.com.au) — NCT01999374 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Type 1 Diabetes

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who previously took part in one of these specific parent studies: 2000/0329; 2000/0196; 2004/0205; 2000/0024; 2006/0200; 2006/0508; or 2006/0210
People who have a working pancreatic islet transplant (the transplanted tissue is still functioning and has not failed) and are still taking anti-rejection medication
People willing to use an approved form of contraception during the study and for 4 months after it ends
People able to sign a written consent form to participate

Who may not be able to join:

Women who are pregnant, currently breastfeeding, or unwilling to use effective contraception for the full study period and 4 months afterward (acceptable methods include the pill, Norplant®, Depo-Provera®, or barrier devices used with spermicide — condoms used alone are not considered acceptable)
Men who plan to try to father a child during the study or within 4 months of finishing, or who are unwilling to use effective contraception during that time
People with any other medical condition that the trial doctor believes would make participation unsafe

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 15 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Rodolfo Alejandro, MD, University of Miami

Phone: 305 243-7740

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT01999374

Sponsor: Rodolfo Alejandro

Phase: Not Applicable

Status: Recruiting

Condition: Type 1 Diabetes

Trial contact: 305 243-7740

More information: https://clinicaltrials.gov/study/NCT01999374

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who previously took part in one of these specific parent studies: 2000/0329; 2000/0196; 2004/0205; 2000/0024; 2006/0200; 2006/0508; or 2006/0210
People who have a working pancreatic islet transplant (the transplanted tissue is still functioning and has not failed) and are still taking anti-rejection medication
People willing to use an approved form of contraception during the study and for 4 months after it ends
People able to sign a written consent form to participate

Who may not be able to join:

Women who are pregnant, currently breastfeeding, or unwilling to use effective contraception for the full study period and 4 months afterward (acceptable methods include the pill, Norplant®, Depo-Provera®, or barrier devices used with spermicide — condoms used alone are not considered acceptable)
Men who plan to try to father a child during the study or within 4 months of finishing, or who are unwilling to use effective contraception during that time
People with any other medical condition that the trial doctor believes would make participation unsafe

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 15 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Rodolfo Alejandro

Registry

ClinicalTrials.gov

Start date

1 March 2013

Est. completion

1 March 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Duration of sustained islet allograft function

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov